Recent Research Analysts’ Ratings Changes for uniQure (QURE)

A number of firms have modified their ratings and price targets on shares of uniQure (NASDAQ: QURE) recently:

• 1/27/2026 – uniQure is now covered by analysts at Barclays PLC. They set an “equal weight” rating and a $31.00 price target on the stock.
• 1/27/2026 – uniQure was upgraded by analysts at Barclays PLC to a “hold” rating.
• 1/21/2026 – uniQure had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/14/2026 – uniQure had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 1/11/2026 – uniQure was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 1/3/2026 – uniQure was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/11/2025 – uniQure had its price target lowered by analysts at Stifel Nicolaus from $50.00 to $40.00. They now have a “buy” rating on the stock.
• 12/8/2025 – uniQure had its price target lowered by analysts at Mizuho from $60.00 to $33.00. They now have an “outperform” rating on the stock.
• 12/8/2025 – uniQure was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/4/2025 – uniQure had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $53.00 price target on the stock.

Insider Buying and Selling at uniQure

In related news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director owned 32,342 shares in the company, valued at $796,260.04. The trade was a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 102,247 shares of company stock worth $2,839,298. Corporate insiders own 4.79% of the company’s stock.

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.